Shares of AstraZeneca plc (LON:AZN) have earned a consensus recommendation of “Hold” from the twenty-one analysts that are presently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, eight have assigned a hold recommendation and eleven have issued a buy recommendation on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is GBX 5,876.14 ($76.78).
Several analysts recently commented on AZN shares. Barclays restated an “overweight” rating and set a GBX 6,600 ($86.24) price target (up previously from GBX 6,500 ($84.93)) on shares of AstraZeneca in a research report on Friday, August 10th. Shore Capital restated a “hold” rating on shares of AstraZeneca in a research report on Wednesday, August 15th. HSBC set a GBX 4,840 ($63.24) price target on shares of AstraZeneca and gave the company a “sell” rating in a research report on Wednesday, August 15th. Jefferies Financial Group set a GBX 6,200 ($81.01) price target on shares of AstraZeneca and gave the company a “neutral” rating in a research report on Thursday, August 16th. Finally, JPMorgan Chase & Co. restated an “overweight” rating and set a GBX 6,500 ($84.93) price target on shares of AstraZeneca in a research report on Tuesday, August 21st.
AZN stock traded down GBX 28 ($0.37) during midday trading on Monday, hitting GBX 5,927 ($77.45). 2,638,281 shares of the stock traded hands, compared to its average volume of 2,310,000. AstraZeneca has a 1-year low of GBX 4,260 ($55.66) and a 1-year high of GBX 5,520 ($72.13).
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Recommended Story: Swap
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.